Purple Biotech (XTAE:PPBT) Total Debt per Share : ₪0.00 (As of Dec. 2024)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Total Debt per Share?

₪0.00 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Purple Biotech's Total Debt Per Share for the quarter that ended in Dec. 2024 was ₪0.00.

Purple Biotech Total Debt per Share Historical Data

The historical data trend for Purple Biotech's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Total Debt per Share Chart

Purple Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Debt per Share

Get a 7-Day Free Trial

0.02

0.01

Purple Biotech Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Debt per Share	Get a 7-Day Free Trial															0.01	-	-	-	-

Purple Biotech Total Debt per Share Calculation

Purple Biotech's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.00	+	0.68)	/	517.13
	=	0.00

Purple Biotech's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.00	+	0.68)	/	517.13
	=	0.00

Purple Biotech Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Total Debt per Share

Comparable Companies

Traded in Other Exchanges

PPBT:USA

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.